30 Oct 2019

3TR Kick-off meeting

COMBINE Group (University of Catania) is one of the partner of 3TR project, the largest-ever Innovative Medicine Initiative 2 (IMI2) immunology project to improve disease management of non-responders to therapy across seven immune-mediated diseases.Read on: Full Description of 3TR and See the video

Read more...
01 Oct 2019

Maintaining European scientific excellence and global leadership in TB Vaccine R&D

Maintaining European scientific excellence and global leadership in TB Vaccine R&DDocument Link

Read more...
04 Jul 2019

STriTuVaD simulation platform now able to reproduce the immune system response induced by vaccines

Another important milestone has been reached by the STriTuVaD project in these days.The team of the University of Catania (Italy) successfully extended their modeling framework in order to include dynamics and specific features of the Mycobacterium Tuberculosis infection and to simulate the artificial immunity induced by candidate vaccines. UISS, acronym for…

Read more...
23 Jan 2019

STriTuVaD consortium meeting lays down the foundations for a fruitful EU-India cooperation in the fight against Tuberculosis

STriTuVaD consortium meeting lays down the foundations for a fruitful EU-India cooperation in the fight against TuberculosisDocument Link

Read more...
17 Dec 2018

STriTuVaD consortium plan its regulatory strategy

STriTuVaD consortium plan its regulatory strategy.#STriTuVaD #insilicotrials #EMA #UISS #regulatoryqualification Document Link

Read more...
14 Dec 2018

Can new drugs be tested with computers? EU-funded team explores the future of tuberculosis drugs testing

Can new drugs be tested with computers? EU-funded team explores the future of tuberculosis drugs testing.#insilicotrials, #StriTuVad, #tuberculosis, #UniCT, #COMBINE Document Link

Read more...
06 Jun 2018

COMBINE Group pioneers one of the first in silico trial approach

The most important financial newspaper in Italy recently published an article about the scientific coordination  of the COMBINE Group in the EC Horizon 2020 funded project STriTuVaD.  

Read more...
17 Mar 2018

STriTuVaD Kick off meeting

Friday, 16 March 2018 On February 1, STriTuVaD project officially started.The StriTuVaD multidisciplinary consortium, will deliver an in silico trial platform to simulate the relevant individual human physiology and physiopathology in patients affected by Mycobacterium tuberculosis. Virtual populations of individuals (a set of libraries of virtual patients for re-use in…

Read more...
13 May 2017

Call for papers: Cancer Immunotherapy and Vaccines

Guest Editor: Professor Francesco Pappalardo BMC Immunology is currently accepting manuscripts to the new thematic series “Cancer Immunotherapy and Vaccines”.The purpose of this thematic series is to bring together the latest advances in both biological and computational research, looking broadly at the basic biological aspects of immunotherapy, emerging immunotherapies (both prophylactic…

Read more...